Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Carcinoma, Renal Cell 36Kidney Neoplasms 9Neoplasm Metastasis 7Neoplasms 6Melanoma 5Colorectal Neoplasms 5Glioblastoma 4Carcinoma, Hepatocellular 4Recurrence 3Clear-cell metastatic renal cell carcinoma 3Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Liver Neoplasms 2Endometrial Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Adenoid Cystic 2cT2a N0NxM0 Renal Tumor 1Uveal Melanoma 1Uterine Cervical Neoplasms 1Solitary Fibrous Tumors 1Solid Malignancies 1Skin Neoplasms 1Sarcoma, Alveolar Soft Part 1Salivary Gland Neoplasms 1Relapsed Pediatric Solid Tumor 1Radiation Therapy 1Prostatic Neoplasms 1Pheochromocytoma 1Paraganglioma 1Ovarian Neoplasms 1

Interventions

lutetium Lu 177 dotatate 43-Iodobenzylguanidine 4anlotinib 3gallium Ga 68 dotatate 2cabozantinib 2Temozolomide 2Sunitinib 2Phenoxybenzamine 2Magnetic Resonance Spectroscopy 2177Lu-octreotide, DOTA(0)-Tyr(3)- 2vandetanib 1pembrolizumab 1olaparib 1lanreotide 1fluorodopa F 18 1fludarabine phosphate 1belzutifan 1atezolizumab 1Vorinostat 1Specimen Handling 1Radiosurgery 1Interleukin-13 1Genetic Testing 1Fluorodeoxyglucose F18 1Everolimus 1Erlotinib Hydrochloride 1Doxazosin 1Cyclophosphamide 1Blood Specimen Collection 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Paraganglioma × Axitinib × Clear all
NCT03839498 2026-03-02

Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma

Columbia University

Phase 2 Active not recruiting
6 enrolled
CNSEndocrine

Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡